Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.

Autor: McGuinness MJ; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand.; Whangārei Hospital, Northland District Health Board, Whangārei, New Zealand., Woodhouse B; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand., Harmston C; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand.; Whangārei Hospital, Northland District Health Board, Whangārei, New Zealand., Parker K; Planning, Funding and Outcomes, Waitematā District Health Board, Waitakere, New Zealand., Kramer N; Department of Pathology, North Shore Hospital, Waitematā District Health Board, Waitakere, New Zealand., Findlay M; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand., Print C; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand., Merrie A; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand.; Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand., Lawrence B; Faculty of Medical and Health Sciences and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand.; Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
Jazyk: angličtina
Zdroj: ANZ journal of surgery [ANZ J Surg] 2022 Jul; Vol. 92 (7-8), pp. 1748-1753. Date of Electronic Publication: 2022 Jun 28.
DOI: 10.1111/ans.17851
Abstrakt: Background: Small intestinal Neuroendocrine Neoplasms (SI-NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI-NEN in Auckland, Aotearoa New Zealand (AoNZ).
Methods: A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data.
Results: One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%) and 61.8% (95% CI 51.8-71.8%), respectively. Ten-year disease-specific survival was 100% for stage I and II, 74% (95%CI 61.7-84.4%) for stage III and 33.9% (95%CI 16.9-35.6%) for stage IV SI-NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92-5.5) nor distant resection (HR 1.72, 95% CI 0.63-4.7) were significantly associated with a disease-specific or overall survival benefit.
Conclusion: This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
(© 2022 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.)
Databáze: MEDLINE
Externí odkaz: